Suven Life Sciences Limited (BOM:530239)
India
· Delayed Price · Currency is INR | Market Cap | 57.61B |
| Revenue (ttm) | 70.62M |
| Net Income (ttm) | -2.75B |
| Shares Out | 263.72M |
| EPS (ttm) | -12.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,035 |
| Average Volume | 41,087 |
| Open | 214.95 |
| Previous Close | 211.55 |
| Day's Range | 214.95 - 229.25 |
| 52-Week Range | 120.45 - 303.00 |
| Beta | 0.30 |
| RSI | 75.52 |
| Earnings Date | May 13, 2026 |
About Suven Life Sciences
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto... [Read more]
Financial Performance
In fiscal year 2025, Suven Life Sciences's revenue was 66.56 million, a decrease of -43.08% compared to the previous year's 116.93 million. Losses were -1.61 billion, 53.0% more than in 2024.
Financial StatementsNews
Pharma sector stocks today, Feb 4: Suven Life Sciences jumps 9%, Aarti Drugs falls 6%, Shilpa Medicare up 2.80%, Mankind Pharma down 2.92%
The pharma sector displayed mixed performance in early trading on February 4, 2026. While some stocks recorded gains, others faced...
Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company developing novel therapies for Central Nervous System (CNS) disorders, has announced a...
Suven Life Sciences shares surge over 8% after clinical trial update
Shares of Suven Life Sciences Limited surged 8% on January 8, reaching ₹139.00 during the trading session. The sharp rise comes after the company announced the dosing of the first subjects in a Phase-...
Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107
Suven Life Sciences Limited has announced the dosing of the first subjects in a Phase-1 clinical trial for SUVN-I6107, a muscarinic M1 positive allosteric modulator (M1 PAM) aimed at treating cognitiv...
Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder
Suven Life Sciences has recently informed exchanges about the positive topline results from its Phase-2a proof-of-concept signal detection open label fixed-dose study that assessed the safety and effi...
Suven Life Sciences announces FDA acceptance of Investigational New Drug
Suven Life Sciences, a clinical stage biopharmaceutical company that discovers and develops novel medicines to treat Central Nervous System (CNS) disorders, has recently announced that the United Stat...